RT Journal Article
T1 The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
A1 Muñoz, Miguel
A1 Coveñas, Rafael
K1 Apoptosis
K1 Antitumor
K1 Antimetastasis
K1 Anti-angiogenesis
K1 NK-1 receptor
K1 Substance P
K1 Drug repositioning
K1 Emend
K1 Antineoplásicos
K1 Genes Supresores de Tumor
K1 Inhibidores de la angiogénesis
K1 Receptores de neuroquinina-1
K1 Sustancia P
K1 Reposicionamiento de medicamentos
K1 Aprepitant
AB Neurokinin-1 receptor (NK-1R) antagonists exert antitumor action, are safe and do not cause serious side-effects. These antagonists (via the NK-1R) exert multiple actions against cancer: antiproliferative and anti-Warburg effects and apoptotic, anti-angiogenic and antimetastatic effects. These multiple effects have been shown for a broad spectrum of cancers. The drug aprepitant (an NK-1R antagonist) is currently used in clinical practice as an antiemetic. In in vivo and in vitro studies, aprepitant also showed the aforementioned multiple antitumor actions against many types of cancer. A successful combination therapy (aprepitant and radiotherapy) has recently been reported in a patient suffering from lung carcinoma: the tumor mass disappeared and side-effects were not observed. Aprepitant could be considered as an intelligent bullet against cancer. The administration of aprepitant in cancer patients to prevent recurrence and metastasis after surgical procedures, thrombosis and thromboembolism is discussed, as is the possible link, through the substance P (SP)/NK-1R system, between cancer and depression. Our main aim is to review the multiple antitumor actions exerted by aprepitant, and the use of this drug is suggested in cancer patients. Altogether, the data support the reprofiling of aprepitant for a new therapeutic use as an antitumor agent.
PB MDPI
YR 2020
FD 2020-09-20
LK http://hdl.handle.net/10668/3686
UL http://hdl.handle.net/10668/3686
LA en
NO Muñoz M, Coveñas R. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer? Cancers. 2020 Sep 20;12(9):2682
DS RISalud
RD Apr 5, 2025